NCT06514716 Intra-articular Corticosteroid Injection in GAE for Knee Knee Osteoarthritis
| NCT ID | NCT06514716 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zagazig University |
| Condition | Knee Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-09-29 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-09-29 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to investigate the effectiveness and safety of intra-articular corticosteroid injection (IACI) in alleviating post-procedural pain and improving early outcomes in patients undergoing geniculate artery embolization (GAE) for knee osteoarthritis (OA). The main questions it aims to answer are: * Does intra-articular corticosteroid injection reduce pain levels post-procedure compared to GAE alone? * Does the combination of GAE and IACI improve functional outcomes and patient-reported outcomes compared to GAE alone? Investigators will compare patients receiving GAE with IACI to those receiving GAE alone to see if the addition of IACI provides superior pain relief and functional improvement. Participants will: * Undergo geniculate artery embolization, with or without intra-articular corticosteroid injection. * Have their pain levels assessed using the Visual Analog Scale (VAS) at 1 week, 2 weeks, and 4 weeks post-procedure. * Complete functional outcome assessments using the KOOS and WOMAC scores. * Report any adverse events throughout the study period.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Diagnosed with knee osteoarthritis (OA) based on clinical and radiographic criteria. * Eligible for geniculate artery embolization (GAE) as determined by the treating physician. * Able to provide informed consent and comply with the study protocol. Exclusion Criteria: * Contraindications to corticosteroid injections or geniculate artery embolization. * Pregnant or breastfeeding women. * Active infection or skin condition at the injection site. * Severe cardiovascular, renal, or hepatic diseases that may affect study participation. * Previous knee surgery within the last 6 months. * Participation in another clinical trial within the last 30 days. * Inability to comply with follow-up visits or complete study assessments.
Contact & Investigator
Ahmed A Bessar, MD, PhD
PRINCIPAL INVESTIGATOR
Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.
Frequently Asked Questions
Who can join the NCT06514716 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06514716 currently recruiting?
Yes, NCT06514716 is actively recruiting participants. Contact the research team at Ahmedawadbessar@gmail.com for enrollment information.
Where is the NCT06514716 trial being conducted?
This trial is being conducted at Zagazig, Egypt.
Who is sponsoring the NCT06514716 clinical trial?
NCT06514716 is sponsored by Zagazig University. The principal investigator is Ahmed A Bessar, MD, PhD at Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.. The trial plans to enroll 60 participants.